Relay Therapeutics Pauses Lirafugratinib Rare Cancer Plans Due to IRA

Relay Therapeutics announced plans Thursday to shift gears, pausing its push for rare cancer and switching focus to the larger tumor-agnostic market. The Boston-based biotech is pointing to the Inflation Reduction Act as a driving factor of its decision.